1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Conexeu Sciences said it completed its 12-month preclinical P.R.O.O.F study of the CXU platform in an animal model, reporting that objectives were met in a cheek facial model and a 200cc-equivalent large-volume model and that injectability and volumizing benchmarks were met. The company is not disclosing detailed findings and plans to submit the full results for peer-reviewed publication. The filing contains no financial results, and the platform is not cleared or approved, so the news is a development update rather than a revenue or earnings event for shareholders.
The 12-month preclinical study met objectives in a small-volume cheek model and a 200cc-equivalent large-volume model, and CXU met injectability and volumizing benchmarks.
Detailed findings and quantitative data are not disclosed; full 12-month results are being prepared for peer-reviewed publication.
The first regulatory step is a predicate-based 510(k) submission for a wound care device, targeted for Q1 2027, subject to testing, manufacturing and documentation.
The filing includes no revenue, earnings or guidance figures.
Penguin Solutions reported third-quarter fiscal 2026 net sales of $478.7 million, up 48% from a year earlier, and GAAP diluted earnings of $0.68 per share compared with a loss of $0.01 per share. The company raised its full-year fiscal 2026 outlook for both net sales and earnings per share, citing AI-driven demand, which is a positive sign for shareholders on the company's headline measures.
Q3 fiscal 2026 net sales were $478.7 million, up from $324.3 million in the year-ago quarter; Integrated Memory sales were $275.1 million.
GAAP diluted EPS was $0.68 versus $(0.01) a year earlier; non-GAAP diluted EPS was $0.84 versus $0.47.
Full-year fiscal 2026 net sales growth outlook is now 22% plus or minus 2%, up from 12% plus or minus 5%; non-GAAP EPS outlook is now $2.60 plus or minus $0.05, up from $2.15 plus or minus $0.15.
Management will discuss results on a conference call and webcast today, July 7, 2026, at 1:30 p.m. Pacific Time.
DigitalOcean said in a July 7, 2026 press release that it expects Q2 2026 revenue growth of about 29%, up from 14% in the same quarter of 2025, and that its remaining performance obligations will exceed $800 million. The company also expects its adjusted EBITDA margin and non-GAAP net income per share to be at or above the high end of its previously provided guidance. These are preliminary, unaudited figures subject to quarter-end closing adjustments, so final results may differ.
Q2 2026 revenue growth expected at about 29%, versus 14% in Q2 2025
RPO expected to exceed $800 million, up more than $550 million in the quarter
Adjusted EBITDA margin and non-GAAP EPS expected at or above the high end of guidance
Secured an additional 20 MW of data center capacity for late 2027 and early 2028
Compass Pathways reported 26-week results from the second Phase 3 COMP006 trial of COMP360 in treatment-resistant depression, saying they confirm rapid onset and durable response. The company said its rolling NDA submission is underway, with final submission expected in Q4 2026 and launch expected in the first half of 2027, subject to FDA approval and DEA rescheduling.
39% of participants in the 25 mg arm reached a clinically meaningful MADRS reduction of at least 25% by Week 6 and maintained benefit through at least Week 26
COMP006 enrolled 581 dosed participants; serious adverse events were 6.3% in the 1 mg arm and 5.7% in the 25 mg arm over 26 weeks
Final NDA submission is expected in Q4 2026, with launch anticipated in the first half of 2027 if FDA approved
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.